Trial
NCT04370509
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, San Francisco
Collaborators
Merck Sharp & Dohme LLC
Condition
Metastatic Clear Cell Renal Cell Carcinoma
Intervention
Axitinib (VEGF-TKI)
Why stopped
Collaborating sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-19